Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(16 sites)
Australia
Research Site 8, Sydney, New South Wales Research Site 7, Melbourne, Victoria Canada
Research Site 2, Montreal, Quebec Research Site 1, Montreal, Quebec Research Site 9, Edmonton France
Research Site 15, Paris, Paris Germany
Research Site 13, Tübingen, Baden-Wurttemberg Research Site 14, Ulm, Baden-Wurttemberg New Zealand
Research Site 4, Auckland Research Site 3, Christchurch Spain
Research Site 10, Barcelona Research Site 11, Barcelona Research Site 12, Seville Taiwan
Research Site 5, Kaohsiung City